# US 2026/0083860 A1 · Compositions and methods for genome editing

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0083860 A1
- Document ID: US20260083860A1
- Status: Published application
- Kind: A1
- Application number: 19/303,777
- Filed: 2025-08-19
- Published: 2026-03-26
- Earliest claimed: 2023-02-21
- Assignees: Poseida Therapeutics, Inc.
- Applicants: Poseida Therapeutics, Inc.
- Inventors: Oscar ALVAREZ; Ming-Yue LEE; Blair B. MADISON
- Web page: https://patentgrep.com/patent/US20260083860A1

## CPC

- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- A61K 9/1271: Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers (liposomes as conjugates {A61K47/6911})
- A61K 9/5123: {Organic compounds, e.g. fats, sugars}
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61P 3/06: Antihyperlipidemics
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 15/52: Genes encoding for enzymes or proenzymes
- C12N 15/62: DNA sequences coding for fusion proteins
- C12N 15/88: using microencapsulation, e.g. using {amphiphile} liposome vesicle
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 35/00: Antineoplastic agents
- C07K 2319/00: Fusion polypeptide
- C07K 2319/09: containing a nuclear localisation signal
- C07K 2319/80: containing a DNA binding domain, e.g. Lacl or Tet-repressor
- C07K 2319/85: containing an RNA binding domain
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Disclosed are methods and compositions for functional genetic modifications at selected sites. Also provided are cell populations, which comprise targeted integration of one or more exogenous polynucleotides, and/or indels at one or more selected gene loci.

## Claims

### Claim 1

A polypeptide comprising the amino acid sequence of SEQ ID NO: 35.

### Claim 2 (depends on 1)

A polynucleotide encoding the polypeptide of claim 1.

### Claim 3 (depends on 2)

A vector comprising the polynucleotide of claim 2.

### Claim 4 (depends on 3)

A pharmaceutical composition comprising the vector of claim 3 and at least one pharmaceutically acceptable excipient or diluent.

### Claim 5

A method of modifying a target sequence in the genome of a plurality of cells comprising introducing to a population of unmodified cells a composition comprising:
a) a polypeptide comprising the amino acid sequence of SEQ ID NO: 35, or a polynucleotide encoding the polypeptide of SEQ ID NO: 35; and
b) at least one guide RNA (gRNA),
thereby generating a modification at the target sequence in the genome, and
wherein 1.1-fold to 50-fold of the plurality of cells comprise the modification at the target sequence in the genome in comparison to a plurality of modified cells introduced with a composition comprising a polypeptide comprising the amino acid sequence of SEQ ID NO: 10 or a polynucleotide encoding the polypeptide of SEQ ID NO: 10.

### Claim 6 (depends on 5)

The method of claim 5, wherein 1.2-fold to 1.8-fold of the plurality of cells comprise the modification at the target sequence in the genome in comparison to a plurality of modified cells introduced with a composition comprising a polypeptide comprising the amino acid sequence of SEQ ID NO: 10 or a polynucleotide encoding the polypeptide of SEQ ID NO: 10.

### Claim 7 (depends on 5)

The method of claim 5, wherein 3-fold to 40-fold of the plurality of cells comprise the modification at the target sequence in the genome in comparison to a plurality of modified cells introduced with a composition comprising a polypeptide comprising the amino acid sequence of SEQ ID NO: 10 or a polynucleotide encoding the polypeptide of SEQ ID NO: 10.

### Claim 8 (depends on 5)

The method of claim 5, wherein the modification at the target sequence in the genome is a deletion, a insertion, a substitution, a inversion and/or a relocation.

### Claim 9 (depends on 5)

The method of claim 5, wherein the composition is encapsulated in at least one lipid nanoparticle comprising:
about 40.75% of a compound of HMA-404 by moles,
about 51.75% of cholesterol by moles,
about 5% of DOPC by moles, and
about 2.5% of DMG-PEG2000 by moles;
wherein HMA-404 is shown in the following structure:
wherein a polynucleotide encoding the polypeptide of SEQ ID NO: 35 is an RNA molecule, and wherein the ratio of lipid to RNA molecule in the at least one nanoparticle is about 120:1 (w/w).

### Claim 10 (depends on 5)

The method of claim 5, wherein the plurality of cells comprise:
(a) a liver cell, preferably wherein the liver cell is a hepatocyte, a hepatic stellate cell, Kupffer cell or liver sinusoidal endothelial cell;
(b) a T-cell, preferably wherein the T-cell is an activated T-cell, a resting T-cell or a stem memory T cell (TSCM cell); or
(c) a hematopoietic stem cell (HSC).

### Claim 11 (depends on 5)

A cell modified according to the method of claim 5.

### Claim 12 (depends on 5)

A composition comprising a population of cells modified according to the method of claim 5.

### Claim 13 (depends on 4)

A method of treating at least one disease or disorder in a subject in need thereof comprising administering to the subject at least one therapeutically effective amount of the pharmaceutical composition of claim 4.

### Claim 14 (depends on 13)

The method of claim 13, wherein the at least one disease or disorder is a liver disease or disorder, preferably wherein the liver disease or disorder is:
(a) a metabolic liver disorder;
(b) a urea cycle disorder (UCD), preferably wherein the UCD is N-Acetylglutamate Synthetase (NAGS) Deficiency, Carbamoylphosphate Synthetase I Deficiency (CPSI Deficiency), Ornithine Transcarbamylase (OTC) Deficiency, Argininosuccinate Synthetase Deficiency (ASSD) (Citrullinemia I), Citrin Deficiency (Citrullinemia II), Argininosuccinate Lyase Deficiency (Argininosuccinic Aciduria), Arginase Deficiency (Hyperargininemia), Ornithine Translocase Deficiency (HHH Syndrome) or any combination thereof.

### Claim 15 (depends on 13)

The method of claim 13, wherein the at least one disease or disorder is cancer.

### Claim 16 (depends on 13)

The method of claim 13, wherein the at least one disease or disorder is hemophilia A.

### Claim 17 (depends on 11)

A method of treating at least one disease or disorder in a subject in need thereof comprising administering to the subject at least one therapeutically effective amount of the cell of claim 11.

### Claim 18 (depends on 17)

The method of claim 17, wherein the at least one disease or disorder is cancer, hemophilia A, or a liver disease or disorder, preferably wherein the liver disease or disorder is:
(a) a metabolic liver disorder;
(b) a urea cycle disorder (UCD), preferably wherein the UCD is N-Acetylglutamate Synthetase (NAGS) Deficiency, Carbamoylphosphate Synthetase I Deficiency (CPSI Deficiency), Ornithine Transcarbamylase (OTC) Deficiency, Argininosuccinate Synthetase Deficiency (ASSD) (Citrullinemia I), Citrin Deficiency (Citrullinemia II), Argininosuccinate Lyase Deficiency (Argininosuccinic Aciduria), Arginase Deficiency (Hyperargininemia), Ornithine Translocase Deficiency (HHH Syndrome) or any combination thereof.

### Claim 19 (depends on 12)

A method of treating at least one disease or disorder in a subject in need thereof comprising administering to the subject at least one therapeutically effective amount of the composition of claim 12.

### Claim 20 (depends on 19)

The method of claim 19, wherein the at least one disease or disorder is cancer, hemophilia A, or a liver disease or disorder, preferably wherein the liver disease or disorder is:
(a) a metabolic liver disorder;
(b) a urea cycle disorder (UCD), preferably wherein the UCD is N-Acetylglutamate Synthetase (NAGS) Deficiency, Carbamoylphosphate Synthetase I Deficiency (CPSI Deficiency), Ornithine Transcarbamylase (OTC) Deficiency, Argininosuccinate Synthetase Deficiency (ASSD) (Citrullinemia I), Citrin Deficiency (Citrullinemia II), Argininosuccinate Lyase Deficiency (Argininosuccinic Aciduria), Arginase Deficiency (Hyperargininemia), Ornithine Translocase Deficiency (HHH Syndrome) or any combination thereof.
